BHC Company Profile and Key Details

Q: Who are the executives of BHC?

Mr. John S. BarresiSenior Vice President, Controller & Chief Accounting OfficerMr. Donald PearlSenior Vice President of Ortho DermatologicsDr. Robert F. ButzVice President of Medical & Scientific AffairsMr. Arthur J. ShannonSenior Vice President and Head of Investor Relations & Global CommunicationsMs. Christina S. Cheng CFASenior Vice President of Investor RelationsMr. Thomas J. AppioChief Executive Officer & DirectorMr. Thomas G. VadakethExecutive Vice President & Chief Financial OfficerMs. Seana CarsonExecutive Vice President & Gen. CounselMr. Mirza DautbegovicSenior Vice President & Chief Operating OfficerMs. Kathleen FitzpatrickSenior Vice President & Chief HR OfficerDr. Tage Ramakrishna M.D.Chief Medical Officer and Pres of R&DMr. Jeff HartnessExecutive Vice President of Market Access, Commercial Operations, Neurology, Generics & Gov. AffairsDr. Graham JacksonSenior Vice President & Chief Quality OfficerMr. Cees HeimanSenior Vice President of Europe & Canada

NYSE : BHC

Bausch Health Companies

$6.16

0.18+3.01%

At Close 4:00 PM

51.01

C+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Bausch Health Companies Inc. (BHC) stock surged +3.01%, trading at $6.16 on NYSE, up from the previous close of $5.98. The stock opened at $5.99, fluctuating between $5.98 and $6.30 in the recent session.

Stock Snapshot

5.98

Prev. Close

2.28B

Market Cap

5.98

Day Low

6.35

P/E Ratio

0.97

EPS (TTM)

2.23

Cash Flow per Share

5.99

Open

370.52M

Number of Shares

6.3

Day High

88.47%

Free Float in %

-2.8

Book Value

1.76M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 10, 2026	5.99	6.31	5.98	6.16	1.74M
Feb 09, 2026	5.90	6.04	5.85	5.98	1.64M
Feb 06, 2026	5.78	5.90	5.77	5.88	1.36M
Feb 05, 2026	5.67	5.81	5.62	5.73	2.27M
Feb 04, 2026	5.77	5.79	5.65	5.66	1.31M
Feb 03, 2026	5.78	5.80	5.59	5.70	1.39M
Feb 02, 2026	5.70	5.85	5.64	5.76	2.08M
Jan 30, 2026	5.59	5.74	5.55	5.74	2.23M
Jan 29, 2026	5.64	5.70	5.56	5.59	1.92M
Jan 28, 2026	5.73	5.74	5.63	5.66	1.73M
Jan 27, 2026	5.83	5.93	5.70	5.72	2.74M
Jan 26, 2026	5.88	5.92	5.77	5.80	2.68M
Jan 23, 2026	6.22	6.24	5.86	5.91	7.96M
Jan 22, 2026	6.67	6.80	6.53	6.57	1.77M
Jan 21, 2026	6.85	6.87	6.56	6.65	2.19M
Jan 20, 2026	6.94	6.94	6.71	6.79	1.97M
Jan 16, 2026	7.27	7.30	6.97	6.98	1.52M
Jan 15, 2026	7.39	7.45	7.20	7.26	1.69M
Jan 14, 2026	7.55	7.73	7.42	7.45	1.29M
Jan 13, 2026	7.53	7.67	7.23	7.50	1.91M

Contact Details

Laval, QC H7L 4A8

Canada

https://www.bauschhealth.com 151 474 46792

About Company

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Stock Peers

ZTS

0.83+0.65%

Zoetis Inc.$128.13 CTLT

Catalent, Inc.$63.48 TARO

0.005+0.01%

Taro Pharmaceutical Industries Ltd.$42.98 TEVA

-0.1-0.29%

Teva Pharmaceutical Industries Limited$34.37 ELAN

0.78+3.14%

Elanco Animal Health Incorporated$25.61 TAK

0.37+2.09%

Takeda Pharmaceutical Company Limited$18.10 PRGO

0.07+0.49%

Perrigo Company plc$14.39 RDY

-0.14-0.99%

Dr. Reddy's Laboratories Limited$14.04 HLN

0.16+1.47%

Haleon plc$11.04 EBS

0.01+0.09%

Emergent BioSolutions Inc.$11.04

Company Overview

Bausch Health Companies Inc. (NYSE:BHC) closed at $6.16 USD, gaining $0.18 (3.01%) from the previous close of $5.98. The stock is currently mid-range between its 52-week high and low $4.25 and $8.69. With a market capitalization of about $2.28 billion, Bausch Health Companies Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.38). Key stats such as the average daily volume over the past year has been around 2.46 million shares, in line with its 52-week average. Headquartered in Laval, QC, Bausch Health Companies Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Thomas J. Appio, the company employs approximately 20,700 people and listed since March 29, 1994. Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -1.04%, SMA50 -8.73%, SMA200 -2.85%). The stock’s 14-day RSI is 46.02 (neutral), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.07% below its high and over 44.94% above its low. Average 10-day trading volume of 1.68 million shares is below the 3-month average of 2.30 million, indicating normal recent market interest.

Valuation Metrics

Bausch Health Companies Inc. trades at a P/E ratio of 6.4, slightly below the S&P 500 average, with a price-to-sales ratio of 0.23 and a price-to-book ratio of -4.1 indicating negative book value, which may reflect financial stress. The P/FCF stands at 2.13, also above market averages.

Dividend & Fair Value

Bausch Health Companies Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $21.26. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Bausch Health Companies Inc. generated EPS of $0.97 over the past year. Five-year average earnings growth is 52.33%. Wall Street analysts project EPS growth of -1.8% annually over the next five years. The latest quarter delivered EPS of $nan. The next quarter is forecast at $1.20. Next year's EPS is expected at $12.53. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $8.00. The high target offers 29.87% upside. The low target suggests 29.87% downside. The mean target is $8.00. This offers 29.87% upside. The prior quarter beat by -7.22%. Over the last six quarters, Apple has recorded several small beats. These include -70.56% in August 01, 2024.

Shareholding & Insider Activity

Bausch Health Companies Inc. has 369.79 million shares outstanding. The public float is 225.63 million shares, elevated short interest at 2.25% of float. This equals 7.71 million shares. The short ratio is 3.92 days. Institutional investors hold 83.21% of the float. Insiders own 11.25%. PAULSON & CO. INC. holds 73.26 million shares, Paulson John has 70.76 million shares and Pearson J. Michael has 1.51 million shares. Over the past six months, insider transactions show net buying. They sold 29.28 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Bausch Health Companies generated $8.76B in revenue, or $24.00 per share. Gross margin was 70.78%, operating margin 11.00%, and net profit margin -6.76%. Returns are negative, with ROA at -2.16% and ROE at 57.93%.
On valuation metrics, Bausch Health Companies trades at a P/E of 6.40, P/S of 0.23 and P/B of -4.10. The current ratio is 1.30 and quick ratio is 0.97. Operationally, the company’s inventory turnover is 1.84 and cash conversion cycle is 209.59 days. Debt-to-equity is -37.24, supported by a cash flow-to-debt ratio of 0.07.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Bausch Health Companies posted revenue of $8.76B, down slightly from $8.12B in the prior quarter. Gross profit was $6.20B (margin 70.78%). Operating income was $963.00M (margin 11.0%). Net income was- $592.00M (EPS - $1.62).
The company ended the quarter with $947.00M in cash and short-term investments, a total debt of $22.39B, and net debt of $21.44B. Total assets were $27.35B, with equity of - $82.00M. Financials further reflected stability, with operating cash flow of $1.03B, free cash flow of $760.00M, and capital expenditures of - $272.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Bausch Health Companies Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.69%, with price expected at $5.07 by February 24, 2026, within a range of $4.71 to $5.43 3-Month Outlook: Projected fall of -63.64%, reaching $2.24 by May 08, 2026, with a range of $1.82 to $2.53. 1-Year Outlook: Projected gain of 223.05%, with price at $19.90 by February 10, 2027, within a range of $11.32 to $28.66.

Key Takeaways

Bausch Health Companies Inc. (NYSE:BHC) shares are flat -2.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Bausch Health Companies Inc. trading at a premium to the broader market with a P/E of 6.4. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $20.88, suggesting 238.96% upside. Our AI forecast model points to short-term weakness (-17.69% over two weeks), a medium-term fall (-63.64% over three months), and a longer-term gain (223.05% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Bausch Health Companies Inc. (BHC) stock price?

Bausch Health Companies Inc. (NYSE: BHC) stock price is $6.16 in the last trading session. During the trading session, BHC stock reached the peak price of $6.30 while $5.98 was the lowest point it dropped to. The percentage change in BHC stock occurred in the recent session was 3.01% while the dollar amount for the price change in BHC stock was $0.18.

BHC's industry and sector of operation?

The NYSE listed BHC is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Bausch Health Companies Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BHC?

Mr. John S. Barresi
Senior Vice President, Controller & Chief Accounting Officer
Mr. Donald Pearl
Senior Vice President of Ortho Dermatologics
Dr. Robert F. Butz
Vice President of Medical & Scientific Affairs
Mr. Arthur J. Shannon
Senior Vice President and Head of Investor Relations & Global Communications
Ms. Christina S. Cheng CFA
Senior Vice President of Investor Relations
Mr. Thomas J. Appio
Chief Executive Officer & Director
Mr. Thomas G. Vadaketh
Executive Vice President & Chief Financial Officer
Ms. Seana Carson
Executive Vice President & Gen. Counsel
Mr. Mirza Dautbegovic
Senior Vice President & Chief Operating Officer
Ms. Kathleen Fitzpatrick
Senior Vice President & Chief HR Officer
Dr. Tage Ramakrishna M.D.
Chief Medical Officer and Pres of R&D
Mr. Jeff Hartness
Executive Vice President of Market Access, Commercial Operations, Neurology, Generics & Gov. Affairs
Dr. Graham Jackson
Senior Vice President & Chief Quality Officer
Mr. Cees Heiman
Senior Vice President of Europe & Canada

How BHC did perform over past 52-week?

BHC's closing price is 44.94% higher than its 52-week low of $4.25 where as its distance from 52-week high of $8.69 is -29.11%.

How many employees does BHC have?

Number of BHC employees currently stands at 20,700.

Link for BHC official website?

Official Website of BHC is: https://www.bauschhealth.com

How do I contact BHC?

BHC could be contacted at phone 151 474 46792 and can also be accessed through its website. BHC operates from 2150 St. ElzEar Boulevard West, Laval, QC H7L 4A8, Canada.

How many shares of BHC are traded daily?

BHC stock volume for the day was 1.76M shares. The average number of BHC shares traded daily for last 3 months was 2.46M.

What is the market cap of BHC currently?

The market value of BHC currently stands at $2.28B with its latest stock price at $6.16 and 370.52M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	20700
Beta	0.38
Sales or Revenue	$8.76B
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

BHC Company Profile and Key Details

Bausch Health Companies

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics